¡Ya estamos en ! Descubre más
icono de IOVA

Iovance Biotherapeutics

13.62 USD
-1.10
7.47%
Al cierre Actualizado 16 oct, 4:00 p.m. EDT
Antes de la apertura del mercado
Después del cierre del mercado
13.63
+0.01
0.07%
1 día
-7.47%
5 días
-6.07%
1 mes
37.99%
3 meses
192.27%
6 meses
258.42%
En lo que va del año
440.48%
1 año
508.04%
5 años
-46.67%
10 años
112.81%
 

Acerca de: Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.

Empleados: 975

Noticias

Positivo
Neutral
Negativo
Sentimiento 3 meses
Positivo 50%
Neutral 41.2%
Negativo 8.8%
Neutral
GlobeNewsWire
hace 7 horas
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
PHILADELPHIA, Oct. 16, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on October 15, 2026 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 111,615 shares of Iovance's common stock to twenty-one new, non-executive employees.
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Negativo
Benzinga
hace 11 días
Top 3 Health Care Stocks That May Collapse In Q4
As of Oct. 5, 2026, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
Top 3 Health Care Stocks That May Collapse In Q4
Positivo
Seeking Alpha
hace 11 días
Iovance: Buy Now Before Many Growth Catalysts Kick In
Iovance raised 2026 revenue guidance to $410–$420 million as Amtagvi adoption accelerates, supported by expanding treatment access, greater physician awareness, and faster manufacturing. Frontline melanoma trials, lung cancer development, and international expansion could broaden Amtagvi's market by at least an order of magnitude from the current peak sales expectation of $1B. Internal manufacturing supports improving margins and narrowing losses. I project gross margins reaching 65–70%, although continued cash burn and potential dilution remain risks.
Iovance: Buy Now Before Many Growth Catalysts Kick In
Positivo
Zacks Investment Research
hace 14 días
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Neutral
GlobeNewsWire
hace 15 días
Iovance Biotherapeutics Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer
Leader in Global Drug Development of T Cell Therapies PHILADELPHIA, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced the appointment of Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer (CMO), effective September 30, 2026.
Iovance Biotherapeutics Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer
Neutral
Zacks Investment Research
hace 16 días
IOVA Stock Hits 52-Week High on Raised Revenue Outlook for 2026
Iovance hits a 52-week high after raising its 2026 revenue outlook to $410-$420 million on strong demand for its marketed therapies.
IOVA Stock Hits 52-Week High on Raised Revenue Outlook for 2026
Positivo
Benzinga
hace 16 días
Iovance Biotherapeutics Stock Pauses After Hitting New 52-Week High: What's Going On?
Shares of Iovance Biotherapeutics Inc. (NASDAQ:IOVA) are trading flat Wednesday morning, taking a breather after Tuesday's surge which pushed the stock to a new 52-week high.
Iovance Biotherapeutics Stock Pauses After Hitting New 52-Week High: What's Going On?
Positivo
Zacks Investment Research
hace 16 días
Iovance Biotherapeutics (IOVA) Surges 31.5%: Is This an Indication of Further Gains?
Iovance Biotherapeutics (IOVA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Iovance Biotherapeutics (IOVA) Surges 31.5%: Is This an Indication of Further Gains?
Positivo
Benzinga
hace 17 días
Iovance Biotherapeutics' Amtagvi Demand Drives 2026 Revenue Guidance Bump, Stock Soars
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) shares are trading higher on Tuesday as the company raises full-year 2026 revenue guidance, bucking a -0.8% slide in the Healthcare sector even as the S&P 500 is down 0.10%.
Iovance Biotherapeutics' Amtagvi Demand Drives 2026 Revenue Guidance Bump, Stock Soars
Neutral
GlobeNewsWire
hace 17 días
Iovance Biotherapeutics Raises Full Year 2026 Revenue Guidance to $410 to $420 Million
New Guidance Represents an Increase of $55 Million at the Midpoint from the Prior Range of $350 to $370 Million Strong U.S. Demand for Amtagvi and Proleukin Drives Increased Outlook PHILADELPHIA, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today raised its full year 2026 total revenue guidance range to $410 to $420 million, driven by strong U.S. demand for Amtagvi® (lifileucel) and Proleukin.
Iovance Biotherapeutics Raises Full Year 2026 Revenue Guidance to $410 to $420 Million
Gráficos de precios implementados con Lightweight Charts™